Burleson & Company, LLC Erasca, Inc. Transaction History
Burleson & Company, LLC
- $384 Million
- Q4 2022
Shares
2 transactions
Others Institutions Holding ERAS
# of Institutions
117Shares Held
74.3MCall Options Held
7.1KPut Options Held
40.1K-
Arch Venture Management, LLC Chicago, IL11.1MShares$25.6 Million33.14% of portfolio
-
Black Rock Inc. New York, NY6.98MShares$16.2 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.17MShares$14.3 Million0.17% of portfolio
-
Artal Group S.A. Luxembourg, N44.72MShares$11 Million0.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.34MShares$10.1 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $283M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...